438 related items for PubMed ID: 10469007
1. Effect of carbenoxolone on the plasma renin activity and hypothalamic-pituitary-adrenal axis in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Irony I, Cutler GB.
Clin Endocrinol (Oxf); 1999 Sep; 51(3):285-91. PubMed ID: 10469007
[Abstract] [Full Text] [Related]
2. Toward better treatment of congenital adrenal hyperplasia.
Speiser PW.
Clin Endocrinol (Oxf); 1999 Sep; 51(3):273-4. PubMed ID: 10469004
[No Abstract] [Full Text] [Related]
3. Flutamide decreases cortisol clearance in patients with congenital adrenal hyperplasia.
Charmandari E, Calis KA, Keil MF, Mohassel MR, Remaley A, Merke DP.
J Clin Endocrinol Metab; 2002 Jul; 87(7):3197-200. PubMed ID: 12107224
[Abstract] [Full Text] [Related]
4. Serum cortisol and 17-hydroxyprogesterone interrelation in classic 21-hydroxylase deficiency: is current replacement therapy satisfactory?
Charmandari E, Matthews DR, Johnston A, Brook CG, Hindmarsh PC.
J Clin Endocrinol Metab; 2001 Oct; 86(10):4679-85. PubMed ID: 11600525
[Abstract] [Full Text] [Related]
5. Requirement of mineralocorticoid in congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency.
Hochberg Z, Benderly A, Kahana L, Zadik Z.
J Clin Endocrinol Metab; 1986 Jul; 63(1):36-40. PubMed ID: 3011843
[Abstract] [Full Text] [Related]
6. A possible defect in the inter-conversion between cortisone and cortisol in prepubertal patients with congenital adrenal hyperplasia receiving cortisone acetate therapy.
Whorwood CB, Warne GL.
J Steroid Biochem Mol Biol; 1991 Oct; 39(4A):461-70. PubMed ID: 1911435
[Abstract] [Full Text] [Related]
7. The hypothalamic-pituitary-adrenal axis in partial (late-onset) 21-hydroxylase deficiency.
Feuillan P, Pang S, Schürmeyer T, Avgerinos PC, Chrousos GP.
J Clin Endocrinol Metab; 1988 Jul; 67(1):154-60. PubMed ID: 2837498
[Abstract] [Full Text] [Related]
8. Failure of cortisone acetate treatment in congenital adrenal hyperplasia because of defective 11beta-hydroxysteroid dehydrogenase reductase activity.
Nordenström A, Marcus C, Axelson M, Wedell A, Ritzén EM.
J Clin Endocrinol Metab; 1999 Apr; 84(4):1210-3. PubMed ID: 10199755
[Abstract] [Full Text] [Related]
9. The effect of growth hormone replacement therapy on adrenal androgen secretion in adult onset hypopituitarism.
Isidori AM, Kaltsas GA, Perry L, Burrin JM, Besser GM, Monson JP.
Clin Endocrinol (Oxf); 2003 May; 58(5):601-11. PubMed ID: 12699442
[Abstract] [Full Text] [Related]
10. The acute effects of a mineralocorticoid receptor (MR) agonist on nocturnal hypothalamic-adrenal-pituitary (HPA) axis activity in healthy controls.
Buckley TM, Mullen BC, Schatzberg AF.
Psychoneuroendocrinology; 2007 May; 32(8-10):859-64. PubMed ID: 17666187
[Abstract] [Full Text] [Related]
11. Plasma renin activity in the management of congenital adrenal hyperplasia.
Griffiths KD, Anderson JM, Rudd BT, Virdi NK, Holder G, Rayner PH.
Arch Dis Child; 1984 Apr; 59(4):360-5. PubMed ID: 6372706
[Abstract] [Full Text] [Related]
12. Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats.
Livingstone DE, Walker BR.
J Pharmacol Exp Ther; 2003 Apr; 305(1):167-72. PubMed ID: 12649365
[Abstract] [Full Text] [Related]
13. Mineralocorticoid activity of carbenoxolone: contrasting effects of carbenoxolone and liquorice on 11 beta-hydroxysteroid dehydrogenase activity in man.
Stewart PM, Wallace AM, Atherden SM, Shearing CH, Edwards CR.
Clin Sci (Lond); 1990 Jan; 78(1):49-54. PubMed ID: 2153495
[Abstract] [Full Text] [Related]
14. Modified-release hydrocortisone is associated with lower plasma renin activity in patients with salt-wasting congenital adrenal hyperplasia.
Tschaidse L, Reisch N, Arlt W, Brac de la Perriere A, Linden Hirschberg A, Juul A, Mallappa A, Merke DP, Newell-Price JDC, Perry CG, Prete A, Rees DA, Stikkelbroeck NMML, Touraine PA, Coope H, Porter J, Ross RJM, Quinkler M.
Eur J Endocrinol; 2023 Jan 10; 188(1):. PubMed ID: 36654495
[Abstract] [Full Text] [Related]
15. Oral hydrocortisone administration in children with classic 21-hydroxylase deficiency leads to more synchronous joint GH and cortisol secretion.
Charmandari E, Pincus SM, Matthews DR, Johnston A, Brook CG, Hindmarsh PC.
J Clin Endocrinol Metab; 2002 May 10; 87(5):2238-44. PubMed ID: 11994370
[Abstract] [Full Text] [Related]
16. Growth hormone replacement inhibits renal and hepatic 11 beta-hydroxysteroid dehydrogenases in ACTH-deficient patients.
Walker BR, Andrew R, MacLeod KM, Padfield PL.
Clin Endocrinol (Oxf); 1998 Aug 10; 49(2):257-63. PubMed ID: 9828916
[Abstract] [Full Text] [Related]
17. Growth of patients with congenital adrenal hyperplasia due to 21-hydroxylase in infancy, glucocorticoid requirement and the role of mineralocorticoid therapy.
Sellick J, Aldridge S, Thomas M, Cheetham T.
J Pediatr Endocrinol Metab; 2018 Sep 25; 31(9):1019-1022. PubMed ID: 30173205
[Abstract] [Full Text] [Related]
18. Deficient inactivation of cortisol by 11 beta-hydroxysteroid dehydrogenase in essential hypertension.
Walker BR, Stewart PM, Shackleton CH, Padfield PL, Edwards CR.
Clin Endocrinol (Oxf); 1993 Aug 25; 39(2):221-7. PubMed ID: 8370136
[Abstract] [Full Text] [Related]
19. Reinstitution of mineralocorticoid therapy in congenital adrenal hyperplasia. Effects on control and growth.
Jansen M, Wit JM, van den Brande JL.
Acta Paediatr Scand; 1981 Mar 25; 70(2):229-33. PubMed ID: 7015786
[Abstract] [Full Text] [Related]
20. Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy.
Cleare AJ, Miell J, Heap E, Sookdeo S, Young L, Malhi GS, O'Keane V.
J Clin Endocrinol Metab; 2001 Aug 25; 86(8):3545-54. PubMed ID: 11502777
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
